Filing Flows › 4D Molecular Therapeutics (FDMT) › Q1 2026
4D Molecular Therapeutics (FDMT) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
4D Molecular Therapeutics (FDMT) reported revenue of $3.0M for the first quarter 2026 (Q1 2026), up 218-fold from a year earlier and -96% from the quarter before.
4D Molecular Therapeutics, Q1 2026: revenue $3.0M (218× year over year), net loss $68.8M, operating cash flow −$68.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.0M | -96% | 218× |
| Operating profit | −$73.6M | -600% | — |
| Net earnings | −$68.8M | -454% | — |
| Operating cash flow | −$68.1M | -339% | — |
What changed
Revenue was $3.0M in Q1 2026, up 21664% year over year and down 96% from the previous quarter.
Operating costs exceeded revenue by $73.6M, an operating margin of -2416.1%. Total costs grew 43% against revenue growth of 21664%. The fastest-growing cost line was Research & development (+60%). The quarter ended with a net loss of $68.8M, after a profit of $19.4M the previous quarter.
Operating cash flow was −$68.1M. Non-cash charges added back $1.3M of depreciation and amortization and $4.5M of share-based compensation. Working capital and other items used $5.1M.
Questions
What was 4D Molecular Therapeutics' revenue in the first quarter 2026?
4D Molecular Therapeutics (FDMT) reported revenue of $3.0M for the first quarter 2026 (Q1 2026), up 218-fold from a year earlier and -96% from the quarter before.